Pancreatic Cancer Research

ResearcherSeoul National UniversityNo recent work listed

Sun‐Whe Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6315-6019; OpenAlex author ID A5048617748. Sources: ClinicalTrials.gov.

Their work

Papers
40 (first author 1, last author 14)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
126
Papers, trials and grants by year

2005: 1 trial · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: 1 paper · 2013: 3 papers · 2014: none · 2015: 2 papers · 2016: 4 papers · 2017: 5 papers · 2018: 7 papers · 2019: 5 papers · 2020: 2 papers · 2021: 4 papers · 2022: 4 papers · 2023: 2 papers

Papers 40

  1. Exocrine pancreatic cancer as a second primary malignancy: A population-based study. Co-author DOI 10.14701/ahbps.23-053↗
  2. Surgical management for elderly patients with pancreatic cancer. Co-author DOI 10.4174/astr.2023.105.2.63↗
  3. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  4. Korean Surgical Practice Guideline for Pancreatic Cancer 2022: A summary of evidence-based surgical approaches Last author DOI 10.14701/ahbps.22-009↗
  5. Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea. Co-author DOI 10.3346/jkms.2022.37.e216↗
  6. First Course of treatment and Prognosis of Exocrine Pancreatic Cancer in Korea from 2006 to 2017. Last author DOI 10.4143/crt.2021.421↗
  7. Pattern of local recurrence after curative resection in pancreatic ductal adenocarcinoma according to the initial location of the tumor. Last author DOI 10.1002/jhbp.854↗
  8. Paradigm shift for defining the resectability of pancreatic cancer. First author DOI 10.14701/ahbps.2021.25.4.451↗
  9. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancre… Co-author DOI 10.4143/crt.2020.928↗
  10. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX. Last author DOI 10.5009/gnl19182↗
  11. Is the New T1 Category as Defined in the Eighth Edition of the AJCC Pancreatic Cancer Staging System an Improvement? Co-author DOI 10.1007/s11605-019-04464-x↗
  12. The Implication of Cytogenetic Alterations in Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm Identified by Fluorescence In Situ H… Co-author DOI 10.5009/gnl19087↗
  13. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. Co-author DOI 10.1002/jhbp.648↗
  14. Establishment and Characterization of 10 Human Pancreatic Cancer Cell Lines Including a HER2 Overexpressed Cell Line. Co-author DOI 10.1097/mpa.0000000000001420↗
  15. Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC): An International Delphi Study Among Patients and Health Care Providers. Co-author DOI 10.1097/sla.0000000000002633↗
  16. Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment. Last author DOI 10.1186/s12885-019-6193-0↗
  17. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Co-author DOI 10.3389/fimmu.2019.00496↗
  18. Multinational validation of the American Joint Committee on Cancer 8th edition pancreatic cancer staging system in a pancreas head cancer cohort. Co-author DOI 10.1002/jhbp.577↗
  19. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Co-author DOI 10.1016/j.pan.2017.11.011↗
  20. Clinical significance of defining borderline resectable pancreatic cancer. Last author DOI 10.1016/j.pan.2017.12.003↗
  21. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospect… Co-author DOI 10.1097/sla.0000000000002705↗
  22. Recent treatment patterns and survival outcomes in pancreatic cancer according to clinical stage based on single-center large-cohort data. Last author DOI 10.14701/ahbps.2018.22.4.386↗
  23. Correction: Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Co-author DOI 10.18632/oncotarget.24175↗
  24. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy. Co-author DOI 10.2214/ajr.17.18310↗
  25. Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1007/s00268-016-3798-1↗
  26. Clinicopathologic and survival differences in younger patients with pancreatic ductal adenocarcinoma-A propensity score-matched comparative analysis. Last author DOI 10.1016/j.pan.2017.08.013↗
  27. Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines. Co-author DOI 10.1097/mpa.0000000000000780↗
  28. Preoperative Assessment of Pancreatic Cancer with FDG PET/MR Imaging versus FDG PET/CT Plus Contrast-enhanced Multidetector CT: A Prospective Preliminary Study. Co-author DOI 10.1148/radiol.2016152798↗
  29. Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer. Last author DOI 10.4174/astr.2017.93.4.186↗
  30. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic canc… Last author DOI 10.1016/j.hpb.2015.06.001↗
  31. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer. Co-author DOI 10.1097/md.0000000000003686↗
  32. Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value. Co-author DOI 10.1111/jgh.13253↗
  33. Outcome Analysis of Chemoradiation in Unresectable Pancreatic Cancer Focusing on Treatment Sequencing Strategy. Co-author DOI 10.21873/anticanres.11125↗
  34. Integrative analysis of multi-omics data for identifying multi-markers for diagnosing pancreatic cancer. Co-author DOI 10.1186/1471-2164-16-s9-s4↗
  35. Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma. Co-author DOI 10.4143/crt.2014.025↗
  36. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associa… Last author DOI 10.1097/mpa.0b013e3182954137↗
  37. Cancer cells with p53 deletion detected by fluorescent in situ hybridization in peritoneal drainage fluid is correlated with early peritoneal seeding in resect… Last author DOI 10.4174/jkss.2013.84.4.209↗
  38. Reconstruction of portal vein and superior mesenteric vein after extensive resection for pancreatic cancer. Co-author DOI 10.4174/jkss.2013.84.6.346↗
  39. Postoperative prognostic predictors of pancreatic ductal adenocarcinoma: clinical analysis and immunoprofile on tissue microarrays. Co-author DOI 10.1245/s10434-012-2277-7↗
  40. Clinical implications of immunohistochemically demonstrated lymph node micrometastasis in resectable pancreatic cancer. Last author DOI 10.3346/jkms.2011.26.7.881↗

Trials 1

  1. Standardization of Surgery on the Pancreatic Cancer Principal investigator NCT00679913↗

Closest collaborators

The 25 strongest of 126 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Young Jang · 28 shared papers, 2011–2021 · strength 2.18
  2. Wooil Kwon · 20 shared papers, 2013–2022 · strength 1.78
  3. Mee Joo Kang · 10 shared papers, 2013–2023 · strength 1.19
  4. Sung‐Sik Han · 5 shared papers, 2013–2023 · strength 0.73
  5. Jae Ri Kim · 6 shared papers, 2017–2021 · strength 0.62
  6. Sang‐Jae Park · 4 shared papers, 2018–2023 · strength 0.60
  7. Hongbeom Kim · 6 shared papers, 2017–2021 · strength 0.59
  8. Young‐Joo Won · 3 shared papers, 2022–2023 · strength 0.54
  9. Hyeong Min Park · 3 shared papers, 2022–2023 · strength 0.54
  10. Do‐Youn Oh · 7 shared papers, 2015–2021 · strength 0.50
  11. Ji Kon Ryu · 6 shared papers, 2012–2021 · strength 0.48
  12. Yong‐Tae Kim · 4 shared papers, 2012–2021 · strength 0.33
  13. Christopher Lee Wolfgang · 4 shared papers, 2018–2020 · strength 0.32
  14. Eui Kyu Chie · 4 shared papers, 2015–2021 · strength 0.28
  15. Seungyeoun Lee · 4 shared papers, 2015–2020 · strength 0.28
  16. Taesung Park · 4 shared papers, 2015–2020 · strength 0.26
  17. Jae Seung Kang · 3 shared papers, 2017–2019 · strength 0.26
  18. Ijin Joo · 4 shared papers, 2015–2018 · strength 0.26
  19. Jin Peng He · 3 shared papers, 2018–2020 · strength 0.24
  20. Sung Whan Ha · 3 shared papers, 2015–2021 · strength 0.22
  21. Seock‐Ah Im · 3 shared papers, 2015–2021 · strength 0.22
  22. Yung‐Jue Bang · 3 shared papers, 2015–2021 · strength 0.22
  23. Woo Hyun Paik · 2 shared papers, 2019–2021 · strength 0.22
  24. Min Su You · 2 shared papers, 2019–2021 · strength 0.22
  25. Sang Hyub Lee · 2 shared papers, 2019–2021 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.